Background and Aim: The role of serum hepatitis B surface antigen (HBsAg) level in determining virological breakthrough (VB) for patients with hepatitis B virus (HBV) infection receiving lamivudine remains unclear. The study aimed to evaluate the impact of serum HBsAg levels on VB among patients receiving lamivudine therapy, especially in a setting of low HBV viral load. Methods: Two hundred sixty-eight consecutive treatment-naïve patients who underwent lamivudine therapy for chronic hepatitis B were enrolled. Factors in terms of VB were analyzed by multivariate analysis. Results: After a median treatment duration of 67.1 weeks, 102 patients had VB. Multivariate analysis showed that positive hepatitis B e antigen (HBeAg) (hazard ratio 2.165, P=0.026) and HBV DNA levels ≥2000 IU/mL after 6 months of lamivudine therapy (hazard ratio 5.236, P=0.001) were independent risk factors predicting VB. The cumulative VB rates stratified by HBeAg-positive and -negative at 3 years were 44.7% and 26.3%, respectively. At 3 years, the cumulative VB rates stratified by the HBV DNA <2000 and ≥2000IU/mL after 6 months of therapy were 25.5% and 79.4%, respectively. For HBeAg-positive patients with serum HBV DNA <2000IU/mL after 6 months of therapy, baseline HBsAg levels ≥20000IU/mL was the only risk factor associated with VB. Conclusions: For chronic hepatitis B patients treated with lamivudine, serum HBV DNA level >2000IU/mL after 6 months of therapy could predict subsequent VB. In patients with lower on-treatment viral load, baseline serum HBsAg level is associated with the emergence of VB, especially for those with serum positive HBeAg.
|頁（從 - 到）||1849-1858|
|期刊||Journal of Gastroenterology and Hepatology (Australia)|
|出版狀態||Published - 12月 2013|